We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia (PREMIER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05214105
Recruitment Status : Recruiting
First Posted : January 28, 2022
Last Update Posted : July 18, 2022
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
University of Illinois at Chicago
University of Memphis
University of North Carolina, Charlotte
Wake Forest University
University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
Kenneth Ataga MD, University of Tennessee

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Condition or disease Intervention/treatment
Sickle Cell Disease Kidney Diseases, Chronic Other: Biospecimen/DNA collection and analysis

Detailed Description:

Sickle cell disease (SCD) is characterized by a vasculopathy affecting multiple end organs, with complications including ischemic stroke, pulmonary hypertension, and chronic kidney disease (CKD). Albuminuria, an early measure of glomerular injury and a manifestation of CKD, is common in SCD and predicts progressive kidney disease. Kidney function decline is faster in SCD patients than in the general African American population. The prevalence of rapid decline, commonly defined as an estimated glomerular filtration rate (eGFR) decline of >3 mL/min/1.73 m2 per year, is ~ 31% in SCD, 3-fold higher than in the general population. Furthermore, high-risk Apolipoprotein 1 (APOL1) variants are associated with an increased risk of albuminuria and progression of CKD in SCD. It is well recognized that kidney disease, regardless of severity, is associated with increased mortality in SCD. The investigators have recently observed that rapid eGFR decline is also independently associated with increased mortality in SCD. Early identification of patients at risk for progression of CKD is important to address potentially modifiable risk factors, slow eGFR decline and reduce mortality.

The investigators have previously reported that machine learning (ML) models can identify patients at high risk for rapid decline in kidney function. In this study, the investigators propose the conduct of a prospective, multi-center study to build a ML-based predictive model for progression of CKD in adults with SCD. A model with high predictive capacity for progression of CKD not only affords risk-stratification, but also offers opportunities to modify known risk factors in hopes of attenuating kidney function loss and decreasing mortality risk.

The overall hypothesis is that ML models utilizing clinical and laboratory characteristics, additional biomarkers and genetic assessments have a higher predictive capacity for progression of CKD than persistent albuminuria alone in adults with sickle cell anemia.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models [PREMIER]
Actual Study Start Date : July 5, 2022
Estimated Primary Completion Date : January 31, 2026
Estimated Study Completion Date : January 31, 2026

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients with sickle cell anemia
Prospective longitudinal study of patients with sickle cell anemia
 Other: Biospecimen/DNA collection and analysis
Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Develop two separate predictive models for progression of CKD (eGFR <90 mL/min/1·73 m2 and ≥25% drop in eGFR from baseline) and rapid eGFR decline (eGFR loss >3·0 mL/min/1·73 m2 per year) over the 12 months following the baseline clinic evaluation. [ Time Frame: 12 months ]
    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits.


Secondary Outcome Measures :
  1. Alternate definitions of CKD progression as eGFR decline <90 mL/min/1·73 m2 and ≥50% drop in eGFR from baseline, and rapid eGFR decline as eGFR loss >5·0 mL/min/1·73 m2 per year will be evaluated. [ Time Frame: 12 months ]
    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits.

  2. Evaluate the effect of APOL1 on the predictive capacity of ML models. Genomic DNA will be extracted from whole blood collected at baseline visits using standard techniques and genotyping will be performed as previously described. [ Time Frame: 12 months ]
    At each visit following the first 12 months, rate of eGFR change will be calculated using data from current and earlier visits


Biospecimen Retention:   Samples With DNA
Routine laboratory tests (CBC and chemistries), cystatin C, pregnancy tests (if female and of child-bearing capacity), urinalysis, spot urine albumin-creatinine ratio, and select plasma and urine biomarkers (ET-1, VEGF and soluble VCAM-1) and kidney function (urinary nephrin, KIM-1) and genomic DNA analyses for APOL1 G1/G2 alleles.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Four hundred patients with SCD (HbSS or HbSB0 thalassemia) between the ages of 18 and 65 who meet the eligibility criteria and provide consent to participate in the study, will be enrolled in this prospective longitudinal trial.
Criteria

Inclusion Criteria:

  1. HbSS or HbSβ0 thalassemia, 18 - 65 years old;
  2. non-crisis, "steady state" with no acute pain episodes requiring medical contact in preceding 4 weeks;
  3. ability to understand the study requirements.

Exclusion Criteria:

  1. pregnant at enrollment;
  2. poorly controlled hypertension;
  3. long-standing diabetes with suspicion for diabetic nephropathy;
  4. connective tissue disease such as systemic lupus erythematosus (SLE);
  5. polycystic kidney disease or glomerular disease unrelated to SCD;
  6. stem cell transplantation;
  7. untreated human immunodeficiency virus (HIV), hepatitis B or C infection; h) history of cancer in last 5 years; i) End-stage renal disease (ESRD) on chronic dialysis; j) prior kidney transplantation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05214105


Contacts
Layout table for location contacts
Contact: Kenneth I Ataga, MD 901-448-2813 kataga@uthsc.edu
Contact: Santosh Saraf, MD 312-996-5680 ssaraf@uic.edu

Locations
Layout table for location information
United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Santosh Saraf, MD       ssaraf@uic.edu   
Principal Investigator: Santosh Saraf, MD         
United States, North Carolina
Wake Forest University Not yet recruiting
Winston-Salem, North Carolina, United States, 27109
Contact: Payal Desai, MD       Payal.desai@osumc.edu   
Sub-Investigator: Payal Desai, MD         
United States, Tennessee
The University of Tennessee Health Science Center Recruiting
Memphis, Tennessee, United States, 38104
Contact: Kenneth Ataga, MD    901-448-2813    kataga@uthsc.edu   
Principal Investigator: Kenneth Ataga, MD         
Sub-Investigator: Robert Davis, MD         
Sub-Investigator: Laila Elsherif, PhD         
Sub-Investigator: Ugochi Ogu, MD         
Sub-Investigator: Marquita Nelson, MD         
Sponsors and Collaborators
University of Tennessee
National Heart, Lung, and Blood Institute (NHLBI)
University of Illinois at Chicago
University of Memphis
University of North Carolina, Charlotte
Wake Forest University
University of North Carolina, Chapel Hill
Investigators
Layout table for investigator information
Principal Investigator: Kenneth I Ataga, MD The University of Tennessee Health Science Center
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Kenneth Ataga MD, Principal Investigator, University of Tennessee
ClinicalTrials.gov Identifier: NCT05214105    
Other Study ID Numbers: 2021-0746
1R01HL159376-01 ( U.S. NIH Grant/Contract )
First Posted: January 28, 2022    Key Record Dates
Last Update Posted: July 18, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified data will be provided to other academic investigators, upon request, for the purposes of non-commercial research, utilizing institutional Material Transfer Agreement (MTA).
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Analytic Code
Time Frame: From time of first patient enrollment to up to 7 years after completion of study.
Access Criteria: Requests for data from academic investigators will be approved by the Executive Committee of the PREMIER Study. Following approval, de-identified data will be shared in a secure manner.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kenneth Ataga MD, University of Tennessee:
Machine Learning Models
Sickle Cell Disease
Chronic Kidney Disease
eGFR
Anemia, Sickle Cell
 Albuminuria
Renal Insufficiency, Chronic
Renal Insufficiency
APOL1
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Anemia
Anemia, Sickle Cell
Hematologic Diseases
Urologic Diseases
 Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
Renal Insufficiency